5月19日周一，诺瓦瓦克斯医药（Novavax）股价盘中大涨29.27%，引发市场广泛关注。这一显著涨幅主要源于美国食品和药物管理局（FDA）对该公司新冠疫苗的最新批准。
据报道，FDA批准了诺瓦瓦克斯的新冠疫苗Nuvaxovid上市，但仅限于特定人群使用。获准使用的对象包括65岁及以上的老年人，以及12至64岁之间至少患有一种可能增加新冠重症风险的潜在疾病的人群。尽管批准范围有限，但这一决定仍被视为公司的重要里程碑。
值得注意的是，这项批准来之不易。此前，FDA曾多次推迟批准决定，使外界一度质疑这款疫苗的市场前景。然而，此次获批不仅为诺瓦瓦克斯开辟了新的市场机会，尤其是在针对高风险群体的疫苗接种方面，还将触发来自赛诺菲的1.75亿美元里程碑付款。这些因素共同推动了投资者的积极反应，导致股价大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.